DexCom, Inc. (DXCM) Stock Forecast
Data as of Aug 1, 2026Healthcare · Current price $83.63 (+12.16%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 13, 2026 | Anthony Petrone | Mizuho Securities | $90.00 | +7.6% |
| Dec 16, 2025 | Mike Kratky | Leerink Partners | $92.00 | +10.0% |
| Dec 2, 2025 | Patrick Wood | Morgan Stanley | $75.00 | -10.3% |
| Nov 3, 2025 | Lee Hambright | Bernstein | $84.00 | +0.4% |
| Oct 31, 2025 | Matt O'Brien | Piper Sandler | $75.00 | -10.3% |
| Oct 31, 2025 | William Plovanic | Canaccord Genuity | $99.00 | +18.4% |
| Oct 21, 2025 | Matt O'Brien | Piper Sandler | $100.00 | +19.6% |
| Oct 15, 2025 | Richard Newitter | Truist Financial | $94.00 | +12.4% |
| Oct 8, 2024 | Shagun Singh | RBC Capital | $120.00 | +43.5% |
| Aug 22, 2024 | Mathew Blackman | Stifel Nicolaus | $100.00 | +19.6% |
| Aug 16, 2024 | Shagun Singh | RBC Capital | $130.00 | +55.4% |
| Jul 29, 2024 | Matt Miksic | Barclays | $113.00 | +35.1% |
| Jul 26, 2024 | Steven Lichtman | Oppenheimer | $115.00 | +37.5% |
| Jul 26, 2024 | Matt O\'Brien | Piper Sandler | $90.00 | +7.6% |
| Jul 26, 2024 | William Plovanic | Canaccord Genuity | $89.00 | +6.4% |
| Jul 26, 2024 | Shagun Singh | RBC Capital | $72.50 | -13.3% |
| Jul 12, 2024 | Mathew Blackman | Stifel Nicolaus | $132.00 | +57.8% |
| Jun 3, 2024 | Steven Lichtman | Oppenheimer | $150.00 | +79.4% |
| May 30, 2024 | Issie Kirby | Redburn Partners | $130.00 | +55.4% |
| Mar 12, 2024 | Shagun Singh | RBC Capital | $165.00 | +97.3% |
Top Analysts Covering DXCM
DXCM vs Sector & Market
| Metric | DXCM | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.21 | 2.25 | 2.42 |
| Analyst Count | 33 | 8 | 19 |
| Target Upside | +5.8% | +16316.2% | +17.1% |
| P/E Ratio | 39.82 | 2.97 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $5.19B | $5.23B | $5.35B | 19 |
| 2027-03-31 | $1.29B | $1.32B | $1.35B | 7 |
| 2027-06-30 | $1.41B | $1.45B | $1.48B | 7 |
| 2027-09-30 | $1.46B | $1.49B | $1.52B | 7 |
| 2027-12-31 | $1.53B | $1.57B | $1.60B | 7 |
| 2028-03-31 | $1.42B | $1.46B | $1.49B | 6 |
| 2028-06-30 | $1.57B | $1.61B | $1.65B | 6 |
| 2028-09-30 | $1.63B | $1.67B | $1.70B | 6 |
| 2028-12-31 | $1.73B | $1.77B | $1.81B | 6 |
| 2029-12-31 | $7.37B | $7.47B | $7.68B | 11 |
| 2030-12-31 | $8.48B | $8.60B | $8.84B | 9 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $2.38 | $2.49 | $2.56 | 15 |
| 2027-03-31 | $0.57 | $0.59 | $0.60 | 10 |
| 2027-06-30 | $0.71 | $0.73 | $0.75 | 6 |
| 2027-09-30 | $0.76 | $0.79 | $0.81 | 7 |
| 2027-12-31 | $0.84 | $0.87 | $0.89 | 6 |
| 2028-03-31 | $0.65 | $0.67 | $0.69 | 7 |
| 2028-06-30 | $0.80 | $0.82 | $0.84 | 7 |
| 2028-09-30 | $0.87 | $0.90 | $0.92 | 12 |
| 2028-12-31 | $0.99 | $1.03 | $1.05 | 7 |
| 2029-12-31 | $4.18 | $4.26 | $4.42 | 2 |
| 2030-12-31 | $4.93 | $5.02 | $5.21 | 5 |
Frequently Asked Questions
What is the analyst consensus for DXCM?
The consensus among 33 analysts covering DexCom, Inc. (DXCM) is Buy with an average price target of $83.80.
What is the highest price target for DXCM?
The highest price target for DXCM is $165.00, set by Shagun Singh at RBC Capital on 2024-03-12.
What is the lowest price target for DXCM?
The lowest price target for DXCM is $28.13, set by Robbie Marcus at J.P. Morgan on 2021-06-09.
How many analysts cover DXCM?
33 analysts have issued ratings for DexCom, Inc. in the past 12 months.
Is DXCM a buy or sell right now?
Based on 33 analyst ratings, DXCM has a consensus rating of Buy (2.21/5) with a +5.8% upside to the consensus target of $83.80.
What are the earnings estimates for DXCM?
Analysts estimate DXCM will report EPS of $2.49 for the period ending 2026-12-31, with revenue estimated at $5.23B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.